Q4 2021 Results
Participants
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
Broad pipeline of novel medicines continued to progress in Q4
Approvals
Readouts and publications
3 INNOVATION
• Negative
• Positive ⚫ Mixed results
SCEMBLIX®
US: CML 3L
Cosentyx
US: JPSA & ERA
LEQVIO
US: Hyperlipidemia
Kesimpta
CN: rMS
Submissions
Alpelisib
US: PROS
177Lu-PSMA-617 EU: mCRPC, post-taxane
KYMRIAH
(tisagenlecleucel)
JP: r/r Follicular lymphoma
for IV infusion
Suspension
Designations
Branaplam
Alpelisib
FDA Fast Track designation in Huntington's disease
FDA Priority Review in PROS
-
Ph3 HS (SUNSHINE and SUNRISE)
Ph3 CSU (PEARL 1 and 2)²
Prevalence Lp(a) (HERITAGE)
Cosentyx®
Ligelizumab
Pelacarsen
lanalumab Ph2b
CosentyxⓇ
Ensovibep
YTB323
PHE885
-
Sjögren's
Ph2 PSA IV (INVIGORATE-2)
Ph2-COVID-19 (EMPATHY)
Ph1 - DLBCL
Ph1 - Multiple myeloma
Major Phase 3 study starts
Remibrutinib
Ligelizumab
MS (REMODEL-1/-2); CSU (REMIX-1/-2)
Food allergy (peanut¹); CINDU (PEARL-PROVOKE)
Selected milestones
1. NCT04984876. 2. Superiority demonstrated vs. placebo but not vs. omalizumab. See last slide for all abbreviations.
13 Investor Relations | Q4 2021 Results
NOVARTIS | Reimagining MedicineView entire presentation